NasdaqGS:CAPRBiotechs
Why Capricor Therapeutics (CAPR) Is Down 10.8% After FDA Clears Key Deramiocel Inspection Step
Capricor Therapeutics recently cleared a key hurdle for its lead Duchenne muscular dystrophy therapy Deramiocel, completing an FDA Pre-License Inspection at its San Diego GMP facility and securing a Prescription Drug User Fee Act (PDUFA) decision date in August for its Biologics License Application.
This combination of regulatory progress, manufacturing readiness, and cash runway reportedly extending through the fourth quarter of 2027 gives Capricor unusual visibility on its ability to fund...